Gene Therapy Market Analysis, Size, Growth, Share, Outlook & Forecast to 2027
The global gene therapy market size is expected to reach USD 6.6 billion by 2027, at a CAGR of 16.6% over the forecast period, according to a new report by Grand View Research, Inc. The approval of early CAR-T-based gene therapy products has created lucrative avenues in product approvals over expanded indications. Clinical trials for T-cell therapies each year has risen exponentially in the recent past. Constant developments in CAR-T cell therapy are recognized as one of the key driving factors for market growth. Although gene therapy has primarily been used for cancer treatment, it increasingly finds application in the treatment of various rare and incurable diseases. Approval of products for non-cancer applications, such as approval of Bluebird Bio’s Zynteglo in June 2019 for βthalassemia, indicates the shift in preferences of companies toward other untapped segments. Gene therapies involve complex molecules and hence manufacturing these molecules is a challenge for developers, particularly in with regard to specialized manufacturing facilities and highly skilled technical personnel. This has created lucrative avenues for contract service providers operating in the space. Gene Therapy Market Report Highlights 
Since viral vectors are the most conventional method for the delivery of genes, several operating players have designed their gene therapy programs based on viral vectors